Will Ranbaxy Tie Up With Teva To Launch Generic Lipitor?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Breaking a long silence, Ranbaxy Laboratories Ltd. Managing Director Arun Sawhney told investors last week that he is "very optimistic" about keeping the U.S. launch date of generic versions of Lipitor (atorvastatin), the largest pharmaceutical brand
You may also be interested in...
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States